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ORIGINAL ARTICLE
Human metapneumovirus virus (hMPV) is a newly
recognized respiratory tract pathogen.1 It is a new
member of the family Paramyxoviridae, subfamily
Pneumovirus. Diseases caused by hMPV are simi-
lar to those caused by human respiratory syncy-
tial virus (RSV), the most common cause of viral
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Background/Purpose: Human metapneumovirus (hMPV) is a newly discovered respiratory pathogen.
This prospective hospital-based study investigated the clinical role and features of hMPV in Taiwan.
Methods: Respiratory specimens collected from hospitalized children with acute respiratory tract infection
between September 1, 2003 and April 10, 2005 were screened for metapneumovirus using real-time reverse
transcription–polymerase chain reaction (RT-PCR). 
Results: During the study period, 930 specimens were obtained from 926 hospitalized children. After exclu-
sion of 200 cases due to lack of clinical evidence of airway infection or diseases with known etiology, 726 were
included in the analysis. Among these, 33 children had a positive result for hMPV infection. The majority of
these patients were admitted during spring and early summer. Twenty-one (63.6%) were younger than 2 years
of age. hMPV accounted for 13.3% of respiratory infections occurring between the ages of 18 and 24 months
and was as common a respiratory pathogen as respiratory syncytial virus (RSV) in that age group. The 11 pa-
tients (33.3%) with underlying diseases had a similar disease course to those without underlying diseases. 
A co-pathogen was found in 11 patients (33.3%). Infected children between 2 and 5 years of age had signifi-
cantly higher titers of hMPV in their respiratory specimens (103.88 copies/μL) than children younger than 
2 years (102.26 copies/μL) (p=0.013) and children older than 5 years (102.25 copies/μL) (p=0.005). hMPV posi-
tive cases were significantly older than those with RSV infection (p=0.002) and had a shorter duration of hos-
pitalization (p=0.001), fewer days of oxygen use (p=0.001) and higher levels of C-reactive protein (p=0.004).
Conclusion: Metapneumovirus circulates in children in northern Taiwan during spring and early summer.
hMPV was the most common respiratory pathogen in children aged between 18 and 24 months hospital-
ized with acute respiratory tract infection. Real-time RT-PCR is a sensitive method for investigating the 
epidemiology and diseases associated with hMPV. [J Formos Med Assoc 2007;106(1):16–24]
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respiratory tract infection in young children.2
Patients infected with hMPV manifest symptoms
and signs ranging from a wheezing bronchiolitis
to respiratory distress requiring assisted ventila-
tion.3 This virus has been shown to infect the 
majority of children in the Netherlands by the age
of 5 years.1 A seroepidemiology study in Japan
revealed that the children had been exposed to
hMPV by the age of 10 years.4
Because hMPV is difficult to culture, a reliable
and rapid diagnostic tool is needed. Reverse 
transcription–polymerase chain reaction (RT-PCR)
has been used to identify this virus in studies of
children or adults with respiratory tract infection
in Australia, Canada, United Kingdom, France and
the United States.3,5–8 These studies indicates that
this virus may be prevalent worldwide. This study
investigated the clinical role and features of
hMPV in hospitalized children in a medical center
in northern Taiwan. The value of real-time RT-PCR
for hMPV detection was also investigated.
Methods
Study design 
This study was conducted in the general pediatric
wards of a medical center in Taipei, Taiwan. Hospi-
talized children younger than 15 years old with
symptoms and signs of acute respiratory tract 
infection (ARTI) were recruited. During hospital-
ization, the children’s signs and symptoms were
recorded using a standardized form. This infor-
mation was reviewed and entered into a database.
Throat swab/nasopharyngeal aspiration (NPA)
samples were collected and cultured for viruses.
Case definitions
Respiratory tract symptoms assessed included
cough, rhinorrhea, sore throat, sneezing, or dys-
pnea. Bronchiolitis was defined as an acute respi-
ratory illness characterized by rhinorrhea, cough,
and diffuse wheezes and rales, with peribronchial
thickening and hyperexpansion on chest radio-
graph if available. Pneumonia was defined as
dyspnea in a patient with focal rales or decreased
breath sounds and the presence of a focal infiltrate
on chest radiograph. Laryngotracheobronchitis
(croup) was defined as an acute lower respiratory
tract infection characterized by hoarseness, cough,
and stridor. Two sets of throat swab/NPA samples
were obtained for viral culture from children with
symptoms/signs of respiratory tract infection.
Young infants (age < 3 months) with tempera-
ture > 38°C without a definite source of infection
were not excluded for lack of symptoms/signs of
respiratory tract infection. One set of the two spec-
imens was promptly inoculated onto cell-culture
monolayers. Aliquots of nasopharyngeal aspirates
were snap-frozen and stored at −70°C for molecu-
lar analysis. The other set of nasopharyngeal aspi-
rate was tested by direct immunofluorescence assay
to detect human RSV (IMAGEN™ Respiratory
Syncytial Virus; DakoCytomation, Cambridgeshire,
UK), parainfluenza viruses type 1 and 3 (IMA-
GEN™ Parainfluenza Virus; DakoCytomation),
or indirect immunofluorescence assay of antigen
detection to detect Chlamydia pneumoniae antigen
(TWAR) (DakoCytomation). Serology of my-
coplasma was performed for patients who pre-
sented with atypical pneumonia (good activity,
no respiratory distress, with/without pneumonia
patch). Positive IgM titer (IgM-specific ELISA,
SeroMP IgM; Savyon, Ashdod, Israel) or a four-fold
rise of complement fixation titer (Virion, Nurzburg,
Germany) in convalescent serum compared with
acute serum (1–2 weeks apart) or titer 1:64 for sin-
gle acute serum were defined as positive. Rapid
urine pneumococcal antigen assay (Binax Now;
Binax Inc., Portland, ME, USA) was performed if
patients presented with pneumonia patch, res-
piratory distress, and leukocytosis with high 
C-reactive protein (CRP).
Data collection 
Demographic data collected included age, sex,
family history, conditions of previous hospital-
ization, referral or none, and underlying disease.
Clinical presentations such as cough, rhinorrhea,
fever, dyspnea, vomiting, diarrhea, decreased
appetite, lethargy, and conjunctiva infection
were recorded, as were the findings of physical
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examination and diagnosis. Data including white
blood cell (WBC) count, differential count, serum
concentration of CRP on admission, and chest 
X-ray findings were recorded. The hospital course
of each patient including the duration of symp-
toms, the value of peak body temperature, oxy-
gen requirement, the date of specimen collection,
necessity for intensive care, ventilator support,
and outcome (complication or mortality) were
also collected.
Molecular analysis
RNA was extracted using QIAmp viral RNA kits
(Qiagen, Hieden, Germany). Real-time RT-PCR
was applied to detect viral RNA using a single
tube RT-PCR kit according to the manufacturer’s
instructions (RNA master hybridization probes;
Roche Applied Science, Mannheim, Germany).
Amplification and detection of RNA were per-
formed with a Lightcycler 2.0 instrument (Roche
Applied Science) with one-step RT-PCR. Each
capillary glass contained a 10 μL reaction mixture
that included 2.6 μL sample RNA, 3.75 μL of an
enzyme mixture and a reaction buffer (Lightcycler
RNA master mix hybridization probes; Roche
Applied Science), 0.5μM sense primer, 0.5μM anti-
sense primer, 3.25 mM Mn [Oac]2, and 0.2 μM
fluorescein hybridization probes (TIB-MOLBIOL,
Berlin, Germany). The primers used in the initial
test of the respiratory specimens were based on
the sequence data of a Dutch strain available
from GenBank (accession no. AF 371367) and
targeted the hMPV N gene.2 The sense primer, 5’-
AACCGTGTACTAAGTGATGCACTC and the anti-
sense primer, 5’-CATTGTTTGACCGGCCCCATAA,
produce an amplicon that corresponds to nucleo-
tides 601–813 of the hMPV N gene. Homology 
between hMPV and RSV RNA genome is only
20%,1 hence, it is sufficiently distinct that its se-
quences do not cross-react with existing nucleic
acid amplification assays. Each set of RT and PCR
reactions contained appropriate negative controls.
The reaction mixtures were exposed to a 20-minute
61°C RT step, 30 seconds of denaturation at 95°C,
and followed by 55 cycles of 95°C for 1 second,
60°C for 15 seconds and 72°C for 13 seconds,
using a channel setting of F2/F1. The specificity
of the obtained fluorescence signal was confirmed
by a melting-curve analysis after each run.
Standard curve
Quantification of hMPV RNA was performed with
five 10-fold serial dilutions of a plasmid containing
the primer-spanning region. Viral RNA was trans-
formed to complementary DNA (cDNA) using
the Thermoscript RT-PCR system (Invitrogen,
Carlsbad, USA). Then, the cDNA was transfected
into the plasmid with 2728 bps using yT&A TA
cloning kit and ECOS™ competent cells (Yeastern
Biotech Co. Ltd., Taipei, Taiwan). The top 10 strain
competent cells were added to the plasmids con-
taining the hMPV cDNA and then grown in
ampicillin (50 μg/mL) containing selective culture
media (yLB agar; Yeastern Biotech Co. Ltd.). After
incubating at 37°C for 11–16 hours, a single col-
ony was selected and subjected to restriction di-
gestion using Eco R1 and Bam H1. The plasmid
DNA concentration was calibrated by spectro-
photometry at 260 nm. Ten-fold serial dilution
with RNAse free water was done, then real-time
RT-PCR was performed. The cycle number cor-
relating to the lowest detectable viral copies 
(5 copies/μL) was around 40 by estimation with
N gene hybridization probe.
Statistical analysis
Significant differences between groups were deter-
mined by Student’s t test for comparison of means,
and χ2 or Fisher’s exact test for comparison of pro-
portions. Analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, IL, USA) for
Windows. All reported p values are two-sided and
p < 0.05 was considered statistically significant.
Results
The cohort
Between September 1, 2003 and April 30, 2005,
930 specimens were obtained from 926 hospi-
talized children. Specimens were obtained at a
mean of 5.8 days after the onset of symptoms.
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18 J Formos Med Assoc | 2007 • Vol 106 • No 1
Human metapneumovirus in children
J Formos Med Assoc | 2007 • Vol 106 • No 1 19
Two hundred cases with no clinical evidence of
airway infection or diseases with known etiology
were excluded from further analysis. These in-
cluded patients suffering from diseases such as
herpangina, hand-foot-mouth disease, encephali-
tis, acute lymphadenitis, or acute gastroenteritis.
The PCR results for hMPV were negative for all of
these excluded cases. The eligible cohort included
726 different hospitalizations/specimens (M:F =
422:304). Respiratory specimens from a total of
33 (4.55%) patients with ARTIs were documented
to harbor hMPV.
Seasonal distribution of hMPV infection
hMPV infections occurred year round with a peak
around late spring to early summer (Figure 1)
during the 20-month study period.
Clinical manifestations of hMPV 
infection in children
The clinical characteristics of the 33 children
(M:F=23:10) with hMPV infection are listed in the
Table. Cough was the leading symptom (97%) fol-
lowed by fever (78.8%) and rhinorrhea (60.6%).
Half of the children had dyspnea (48.5%). Diar-
rhea (15.2%), vomiting (12.1%), rash (6.1%),
infection of conjunctiva (6.1%) and sore throat
(6.1%) were also noted. Evidence of either upper
or lower respiratory tract infection or both includ-
ing rhonchi (48%) and rales (55%) was noted on
auscultation in half of the children; 40% of the
children had wheezing, one-third had chest wall
retraction (33%) and stridor was audible in 21%.
The median age at admission was 20 months
old and 21 patients (63%) were younger than 
2 years. Other family members were also suffer-
ing from acute illness in 42.3% of the hMPV-
infected children. Most patients were discharged
uneventfully after a mean duration of hospital-
ization of 4.7 days. One 6-month-old girl with
thoracic dystrophy needed intensive care for 4
days but without intubation. Nevertheless, oxy-
gen therapy was needed in half of children
(17/33, 51.5%), with a mean duration of therapy
of 3.7 days. Chest X-ray was abnormal in 81.8%
of the children with findings including emphyse-
matous change, infiltration, patch and steeple
signs. Antibiotics were prescribed in 57.6% of the
children for clinical evidence of otitis media in
five, sinusitis in two, and suspicion of bacterial
pneumonia in 12.
The clinical diagnoses at the time of admis-
sion and discharge were as follows: pneumonia
(45%), bronchiolitis (21%), acute otitis media
(15%), nasopharyngitis (12%), asthma (6%)
and sinusitis (6%). Notably, some patients had
more than two diagnoses.
Age distribution of hMPV positive cases
Ninety percent of the hMPV positive children
were < 5 years old. Furthermore, 24.2% of hMPV
positive children were aged between 18 and 24
months, while the proportion of those aged 18–
24 months was only 8.1% (p < 0.001). hMPV was
the leading pathogen among children with ARTI
aged 18–24 months (13.1%, 8/61), as important
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Figure 1. Seasonal distribution of cases of human metapneumovirus acute respiratory tract infection during the 20-month
study period.
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Table. Comparison of demographic and clinical characteristics of hospitalized children with human
metapneumovirus (MPV) infections and those with human respiratory syncytial virus (RSV) infections*
MPV positive (n = 33) RSV positive (n = 91) p
Age (mo) 31.8 ± 30.7 13.1 ± 13.7 0.002†
Sex (M/F) 23/10 58/33 0.538
Underlying disease 12 (36.4) 30 (33.0) 0.724
Duration of hospitalization (d) 4.7 ± 2.0 6.2 ± 2.9 0.001†
ICU care 1 (3.0) 13 (14.3) 0.11
O2 use 17 (51.5) 70 (76.9) 0.006†
Duration of O2 use (d) 1.9 ± 2.2 3.9 ± 3.2 0.001†
Intubation 0 2 (2.2) 1.000
Fever 26 (78.8) 68 (74.7) 0.641
Fever duration (d) 3.6 ± 3.0 4.2 ± 3.7 0.441
Cough duration (d) 14.5 ± 7.1 14.0 ± 8.5 0.765
Adult family history of ARIs 10/27 (37.0) 44/78 (56.4) 0.083
Abnormal chest X-ray 27 (81.8) 72 (79.1) 0.487
Co-pathogen identified 12 (36.4) 20 (22.0) 0.106
Differential count (%)
Segment 54.1 ± 20.0 35.7 ± 19.3 0.000†
Lymphocyte 31.4 ± 18.1 52.5 ± 31.5 0.001†
C-reactive protein (mg/dL) 2.73 ± 3.62 0.76 ± 1.2 0.004†
*Data presented as mean ± standard deviation or n (%); †p < 0.05 (χ2 test). ICU = intensive care unit; ARIs = acute respiratory 
infections.
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Figure 2. Proportional distribution of human metapneumovirus (MPV) and human respiratory syncytial virus (RSV) 
infections in different age groups.
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as RSV (13.1%, 8/61) (Figure 2). In contrast to
hMPV, RSV was more prevalent in infants (0–12
months old, p < 0.001); 26.9% of infants with
ARTIs were RSV positive. hMPV was an impor-
tant etiology in hospitalized children < 2 years of
age, accounting for 5.7% of ARTIs.
Underlying diseases in hMPV positive cases
Eleven (33.3%) children infected with hMPV
had underlying diseases, including biliary atresia
with liver cirrhosis in one, intestinal lymphang-
iectasis with protein losing enteropathy in one,
corrected transposition of great arteries with pul-
monary stenosis in one, ventricular septal defect
with pulmonary stenosis in one, vertebral, ano-
rectal, cardiac, tracheal, esophageal, renal, limb
(VACTERAL) association in one, hepatomegaly
in one, Prader-Willi syndrome in one, Jeune tho-
racic dystrophy in one and prematurity in three.
There was no significant difference between hMPV
infected children with or without underlying dis-
ease with regard to hospitalization course, dura-
tion of oxygen requirement, duration of fever, and
CRP level.
Pathogens other than hMPV
hMPV was the sole pathogen in 22 (66.7%) cases.
Other pathogens were detected in 11 cases, includ-
ing adenovirus, RSV, enterovirus, coronavirus
NL-63, M. pneumoniae and S. pneumoniae. Co-
infection did not significantly impact the hos-
pitalization duration, fever duration, WBC count,
or CRP levels of patients with hMPV infection.
Quantification of MPV in respiratory
specimens
The mean viral titer of the 33 positive specimens
was 102.65 copies/μL (range, 100.5 to 105). The
mean titer of the 22 specimens for which hMPV
was the only respiratory virus detected was 102.66
copies/μL compared to 102.64 copies/μL in the 11
dually infected samples (p = 0.968). Viral loads
of hMPV in respiratory specimens were not sig-
nificantly associated with factors including sex,
underlying disease, fever, family history, and
oxygen therapy (Figure 3). Children between 2
and 5 years of age had significantly higher hMPV
titer in their respiratory specimens (mean, 103.88
copies/μL) than children < 2 years old (mean,
P.C. Chan, et al
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102.26 copies/μL) (p = 0.013) and children > 5 years
old (mean, 102.25 copies/μL) (p = 0.005).
Comparison with RSV infection
Two children with RSV infection required intu-
bation and respiratory support while none of 
the hMPV infected children did (Table). No other
complications were observed in these two groups.
Compared to RSV infected children, hMPV infected
children were older (p = 0.002), had shorter dura-
tion of hospital stay (p = 0.001), shorter duration
of oxygen requirement (p = 0.001) and higher
level of CRP (p = 0.004). Similar rates of identifi-
cation of co-pathogens were observed in these
two groups.
Discussion
ARTIs are major causes of morbidity and mortality
in children. Even after extensive laboratory inves-
tigations, about half of ARTIs have no identifiable
etiologic agent.9,10 hMPV is a newly discovered
viral pathogen and its clinical epidemiology and
impact have yet to be fully defined. This virus has
been shown to be circulating in many Asian and
Western countries.3–8,11–13 The present study found
that 4.6% of children hospitalized due to ARTIs
at a medical center in northern Taiwan were in-
fected with hMPV. This rate is similar to what has
been reported in other countries, including 3.9%
in the United States,13 5.5% in Hong Kong,12 and
6.2% in Italy.10,11
Real-time PCR has become an important tool
in the study of infectious diseases, especially for
a newly identified virus that is difficult to grow
in cell culture. A study by Mackay et al showed
that real-time RT-PCR improved the detection 
of virus compared with conventional RT-PCR.2
Although identification of viral nucleic acid in
respiratory specimens does not prove that hMPV
is responsible for patients’ illnesses, the associa-
tion between respiratory tract illness and presence
of the virus suggests a causative role.13 Further-
more, hMPV does not appear to be associated with
asymptomatic carriage in the nasopharynx since
no hMPV was found in respiratory samples from
asymptomatic children < 2 years old.1 In addition
to its improved sensitivity and specificity, RT-PCR
specific for the N gene has been shown to be more
sensitive than RT-PCR for genes L, F, M and P of
hMPV.9,14
The seasonal occurrence of hMPV infection
largely overlaps with that of RSV infections. hMPV
is considered to be a pathogen from December
till May in North America and the United
Kingdom.3,8,15 In the present study, hMPV infec-
tion peaked in late spring and early summer.
Similar seasonal patterns have been observed in
Hong Kong, Canada and Japan.12,16,17 A study
from Tennessee noted that infections began in
March and peaked in May, with some disease ac-
tivity in June and September, which was quite
similar to our results.18 In the present study, spo-
radic hMPV infection also occurred outside of the
peak seasons during the 20-month study period.
Possible reasons for the seasonal pattern may in-
clude multiple circulating strains of hMPV, climate
change, and demographic factors. Phylogenetic
study and long-term prospective study are needed
to clarify the responsible factors.10
Previous studies showed that co-infection of
RSV or other respiratory pathogens with hMPV oc-
curred in 10–75% of subjects.10,19–21 Co-infecting
viral agents found in hMPV-infected sympto-
matic individuals include adenovirus, RSV, in-
fluenzae A and B, and measles.5,22 Among these,
dual infections with hMPV and RSV seem to in-
crease disease severity.19,20 In this study, one-third
of the hMPV-infected cases had other pathogens
identified during the episode of ARTIs. There was
no significant difference in severity of infection,
however, between patients with dual infections
and single hMPV infection. Furthermore, the viral
titers of hMPV in specimens from patients with
single infection were equal to those of patients
with dual infection. We could not confirm whether
dual infection with hMPV and RSV is more severe
because there was only one such case in our co-
hort. Nevertheless, comparison of characteristics
between patients with single RSV and hMPV infec-
tions showed that RSV infected younger children,
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led to a more prolonged hospitalized course and
higher oxygen demand.
Kuypers et al reported that children aged
7–12 months were most likely to be infected
with hMPV and had significantly higher titers 
of hMPV in respiratory specimens.21 However, in
the present study, children aged 18–24 months
had the highest prevalence, but children aged
2–5 years had the highest viral load. The present
study and Kuyper et al’s study are not directly
comparable since their series included both in-
patients (76%) and outpatients (24%), while we
studied inpatients only. Overall, the data suggest
that hMPV may behave differently in different 
regions.
Thanasugarn et al reported progression to 
respiratory distress in two hMPV-infected chil-
dren who had pre-existing bronchopulmonary 
dysplasia and truncus arteriosus status post total
correction.23 These cases suggest that hMPV can
cause life-threatening disease, particularly in
high-risk groups or immunocompromised hosts.24
Nevertheless, among the one-third of cases with
underlying diseases in the present study, no severe
complications were noted.
This study was limited to screening respiratory
samples collected from hospitalized patients.
Hence, we could not determine the population-
based incidence and prevalence. Likewise, sensi-
tivity and specificity of real-time RT-PCR could
not be analyzed as virus culture was not used as a
gold standard. Recently, four distinct genetic lin-
eages (A1, A2, B1 and B2 lineages) of hMPV have
been described.25 Each year, the prevalences of
infections caused by these four lineages of hMPV
have varied.10 The primers used in this study
might miss some viruses of the hMPV B lineage.
Hence, this study may have underestimated the
prevalence of hMPV infection.
In summary, this study has confirmed that
hMPV does circulate in Taiwan, accounting for
4.6% of ARTIs in hospitalized children. The out-
comes of the infected children were good without
complications. Real-time RT-PCR is a sensitive and
effective diagnostic tool for identifying hMPV 
infection.
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